Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer. (Q33407669)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

Erik van Werkhoven

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

5

object named as

Jos H Beijnen

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Alwin D R Huitema

3

object named as

Alwin D R Huitema

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Jan H M Schellens

6

object named as

Jan H M Schellens

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Suzanne Leijen

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Stephan A Veltkamp

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

0 references

publication date

9 May 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

130

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

511-517

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Advanced breast cancer: a phase II trial with gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Understanding ribonucleotide reductase inactivation by gemcitabine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Nucleoside transporters in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Cytosine arabinoside influx and nucleoside transport sites in acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Design and analysis of phase I clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Flat dosing of carboplatin is justified in adult patients with normal renal function.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Model of chemotherapy-induced myelosuppression with parameter consistency across drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Phase I–II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.001

7 January 2021

Identifiers

10.1016/J.YGYNO.2013.05.001

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33407669&oldid=2143563413"